» Articles » PMID: 15083784

A Catalog of Dermatology Utilities: a Measure of the Burden of Skin Diseases

Overview
Publisher Elsevier
Specialty Dermatology
Date 2004 Apr 16
PMID 15083784
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Utilities are measures of quality of life that reflect the strength of individuals' preferences or values for a particular health outcome. As such, utilities represent a measure of disease burden. The aim of this article is to introduce the concept of utilities to the dermatology community and to present a catalog of dermatology utilities obtained from direct patient interviews. Our data are based on 236 total subjects from Grady Hospital (Atlanta, GA), Stanford Medical Center (Palo Alto, CA), and Parkland Hospital (Dallas, TX). The mean time trade-off utilities ranged from 0.640 for blistering disorders to 1.000 for alopecia, cosmetic, and urticaria. The mean utility across all diagnoses was 0.943. We present utilities for 17 diagnostic categories and discuss the underlying reasons for the significant disease burden that these utilities represent. We also present these dermatology categories relative to noncutaneous diseases to place the cutaneous utilities in perspective and to compare the burden of disease. We have demonstrated that skin diseases have considerable burden of disease and provided a preliminary repository of utility data for future researchers and policy makers.

Citing Articles

Comparison of health-related quality of life in atopic dermatitis, hidradenitis suppurativa, pemphigus and psoriasis.

Balazs P, Gaspar K, Gergely H, Hajdu K, Hollo P, Koszoru K Arch Dermatol Res. 2025; 317(1):291.

PMID: 39825944 PMC: 11742771. DOI: 10.1007/s00403-024-03786-4.


Burden of chronic skin disease from an Asian perspective: Assessment of health state utilities and quality of life in a Singapore cohort.

Yew Y, Barbieri J, Chen S JAAD Int. 2024; 17:86-93.

PMID: 39399334 PMC: 11471223. DOI: 10.1016/j.jdin.2024.07.020.


Toenail Onychomycosis with or without Diabetes in Canada: Patient Treatment Preferences and Health State Utilities.

Mickle A, Lozano-Ortega G, Gaudet V, Popoff E, Barbeau M, Mathieu S Patient Prefer Adherence. 2024; 18:475-486.

PMID: 38410773 PMC: 10896105. DOI: 10.2147/PPA.S450215.


Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.

Bindra J, Chopra I, Hayes K, Niewoehner J, Panaccio M, Wan G Clinicoecon Outcomes Res. 2023; 15:739-752.

PMID: 37868649 PMC: 10590138. DOI: 10.2147/CEOR.S428466.


The Cost Utility of Nonpregnancy Laboratory Monitoring for Persons on Isotretinoin Acne Therapy.

Borre E, Chen S, Nicholas M JID Innov. 2023; 3(3):100186.

PMID: 37252320 PMC: 10213960. DOI: 10.1016/j.xjidi.2023.100186.